On May 28, 2024, the Board of Directors of the general partner (the “General Partner”) of Black Stone Minerals, L.P. (the “Partnership”) and Evan Kiefer, Senior Vice President, Chief Financial Officer, and Treasurer of the General Partner, agreed that Mr. Kiefer would depart his current roles at the general partner effective May 28, 2024.
The Board of Directors has appointed Taylor DeWalch as Senior Vice President and Chief Financial Officer of the General Partner and Dawn Smajstrla as Treasurer of the General Partner, effective May 28, 2024.
Departed
Christopher Krawtschuk
Chief Financial Officer
bluebird bio, Inc.
Effective
2024-06-10
Successor
O. James Sterling
Filed
May 29, 2024, 7:59 PM ET
Effective June 10, 2024 (the “Separation Date”), Christopher Krawtschuk will depart bluebird bio, Inc. (the “Company”) and cease serving as Chief Financial Officer and principal accounting officer.
Appointed
O. James Sterling
Chief Financial Officer
bluebird bio, Inc.
Effective
2024-06-10
Filed
May 29, 2024, 7:59 PM ET
On May 28, 2024, the Board of Directors (the “Board”) appointed O. James Sterling as Chief Financial Officer of the Company and designated Mr. Sterling as principal accounting officer, effective as of the date Mr. Sterling commences employment with the Company, which is expected to be June 10, 2024 (the “Transition Date”).
Role change
Dane E. Whitehead
Executive Vice President and Chief Financial Officer
MARATHON OIL CORP
Filed
May 29, 2024, 7:59 PM ET
On February 27, 2024, Marathon announced that Dane E. Whitehead, Executive Vice President and Chief Financial Officer of Marathon had informed Marathon of his intention to retire from Marathon effective July 1, 2024. Marathon and Mr. Whitehead agreed to delay his departure and Mr. Whitehead will remain an Executive Vice President and Advisor to the CEO
Effective May 28, 2024, the Board of Directors of American Realty Investors, Inc. (the “ Company ” or the “ Issuer ” or “ ARL ”) appointed Erik L. Johnson, age 56, President and Chief Executive Officer of the Company.
Appointed
Erik L. Johnson
President and Chief Executive Officer
IOR ·
INCOME OPPORTUNITY REALTY INVESTORS INC /TX/
Effective
2024-05-28
Successor
Bradley J. Muth
Filed
May 29, 2024, 7:59 PM ET
Effective May 28, 2024, the Board of Directors of Income Opportunity Realty Investors, Inc. (the “ Company ” or the “ Issuer ” or “ IOR ”) appointed Erik L. Johnson, age 56, President and Chief Executive Officer of the Company.
Departed
Bradley J. Muth
President and Chief Executive Officer
IOR ·
INCOME OPPORTUNITY REALTY INVESTORS INC /TX/
Effective
2023-04-14
Successor
Erik L. Johnson
Filed
May 29, 2024, 7:59 PM ET
the April 14, 2023 resignation of Bradley J. Muth, age 68, from the offices of President and Chief Executive Officer.
Effective May 28, 2024, the Board of Directors of Transcontinental Realty Investors, Inc. (the “ Company ” or the “ Issuer ” or “ TCI ”) appointed Erik L. Johnson, age 56, President and Chief Executive Officer of the Company.
Alton Lewis will retire from his role as President and Chief Executive Officer of First Guaranty Bancshares, Inc. and First Guaranty Bank. Mr. Lewis will continue to serve as Vice Chairman of the First Guaranty Bancshares, Inc. and First Guaranty Bank Board of Directors.
On May 24, 2024, Tom McKinlay, Chief Executive Officer of the Company, informed the Company he will retire as Chief Executive Officer of the Company, effective September 30, 2024.
On May 28, 2024, the Board appointed Paul Chang, the Company’s Global President, as the Co-Chief Executive Officer of the Company, effective immediately, with full power and authority of a Chief Executive Officer as prescribed in the Bylaws of the Company, to serve in such capacity until his successor is elected and qualified or until his earlier death, resignation, or removal
concurrently with such appointment, Mr. Michael Zacharski, who currently serves as the Company’s Chief Executive Officer, will become Co-Chief Executive Officer.
Role change
Vikram Grover
Chief Financial Officer
HIMALAYA TECHNOLOGIES, INC
Effective
2024-05-21
Successor
Ryan Nguyen
Filed
May 29, 2024, 7:59 PM ET
On May 21, 2024, Vikram Grover resigned his positions as CEO, Treasurer, Controller and Director but will remain CFO pending a transition to new management.
Appointed
Ryan Nguyen
Chief Executive Officer and Director
HIMALAYA TECHNOLOGIES, INC
Effective
2024-05-20
Filed
May 29, 2024, 7:59 PM ET
On May 20, 2024, we named Ryan Nguyen, an industry expert in Web3 platforms and cryptocurrencies, as CEO and Director.
As previously announced, effective April 30, 2024, Monica Diaz Brickell left AXIL Brands, Inc. (the “Company”), including her position as the Chief Financial Officer of the Company.
On May 23, 2024, Robert Enslin informed UiPath, Inc. (the “Company”) of his resignation from the Board of Directors of the Company (the “Board”) and from his position as Chief Executive Officer (“CEO”) of the Company, effective June 1, 2024
Mark C. Fuller, President and Chief Executive Officer ("CEO") of Castellum, Inc. (the "Company") will be stepping down from those positions effective July 1, 2024 to pursue other interests.
Stephen D. Griffin, Senior Vice President and Chief Financial Officer of VSE Corporation (the “Company”), notified the Company of his decision to resign from his positions with the Company, effective May 29, 2024
On May 27, 2024, the board of directors (the “ Board ”) of the Company appointed Joel R. Jung as Interim Chief Financial Officer and designated Mr. Jung as the Company’s principal financial officer and principal accounting officer, effective as of May 28, 2024.
On May 24, 2024, O. James Sterling tendered his resignation from his position as the Chief Financial Officer of Renalytix plc (the “ Company ”).
Appointed
Mark A. Kowieski
Chief Financial Officer
Evoke Pharma Inc
Effective
2024-05-22
Filed
May 28, 2024, 7:59 PM ET
On May 22, 2024, the Board appointed Mr. Kowieski, age 47, as Chief Financial Officer ("CFO") of Evoke Pharma, Inc. (the "Company") effective May 22, 2024.
On May 28, 2024, the Company also announced the appointment, effective immediately, of Susan Landi as the Company’s new Chief Financial Officer and Treasurer.
On May 28, 2024, Farmland Partners Inc. (the “Company”) announced that the Company and James Gilligan, the Company’s Chief Financial Officer and Treasurer, mutually agreed to separate.
On May 28, 2024, the Board of Directors appointed Thomas Schuetz, MD, PhD, then-current President of Research and Development and Vice Chair of the Board of Directors of the Company, as President and Chief Executive Officer of the Company, and as Principal Executive Officer, Principal Financial and Principal Accounting Officer of the Company, effective immediately.
On May 28, 2024, Vered Bisker-Leib, PhD, MBA, resigned as Chief Executive Officer (Principal Executive Officer and Principal Financial and Accounting Officer) and resigned as a member of the Board of Directors, of Compass Therapeutics, Inc. (the “Company”) effective the same date.
Appointed
(interim)
Thomas Langan
Interim Chief Executive Officer
Veradigm Inc.
Effective
2024-06-07
Filed
May 28, 2024, 7:59 PM ET
Effective as of the Initial Term Date, the Board appointed Mr. Thomas Langan as Interim Chief Executive Officer of the Company, and the Board reduced the size of the Board from seven directors to six directors.
Role change
(interim)
Leland Westerfield
Interim Chief Financial Officer
Veradigm Inc.
Filed
May 28, 2024, 7:59 PM ET
On May 27, 2024, the Company entered into an extension letter agreement (the “Extension Agreement”) with Mr. Westerfield to extend his appointment through December 31, 2024.
appointment of Kyle Gano, Ph.D., age 51, to serve as Neurocrine’s President and Chief Executive Officer, effective as of the Transition Date.
Departed
Clint Sever
Chief Executive Officer and Co-Founder
Cue Health Inc.
Effective
2024-05-24
Filed
May 28, 2024, 7:59 PM ET
As of May 24, 2024, the Company terminated all of its employees and executive officers, including Chief Executive Officer and Co-Founder Clint Sever, Chief Business Officer Chris Achar and Chief Accounting Officer Randall Pollard.
On May 28, 2024, Aviat Networks, Inc. (the “Company”) announced the appointment of Michael Connaway as the Company’s Senior Vice President and Chief Financial Officer.
Appointed
Han-Wen Ou
Chief Executive Officer, Chief Financial Officer, Secretary and sole Director
Redox International Group, Corp.
Effective
2024-05-16
Filed
May 28, 2024, 7:59 PM ET
Dr. Han-Wen Ou was appointed as Chief Executive Officer, Chief Financial Officer, Secretary and sole Director.
Appointed
Jay Nutt
Executive Vice President, Chief Financial Officer and Treasurer
On May 22, 2024, Cactus, Inc. (the “Company”) appointed Jay Nutt as the Company’s Executive Vice President, Chief Financial Officer and Treasurer, with an anticipated start date of June 3, 2024.
Mr. Nutt will replace Alan Keifer, who has been serving as the Company’s Interim Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer.
Role change
Mina Kim
Chief Executive Officer
ACELYRIN, Inc.
Effective
2024-05-09
Filed
May 28, 2024, 7:59 PM ET
Effective May 9, 2024, Mina Kim was appointed as the Chief Executive Officer of the Company
Departed
Shao-Lee Lin, M.D., Ph.D.
Chief Executive Officer
ACELYRIN, Inc.
Effective
2024-05-08
Successor
Mina Kim
Filed
May 28, 2024, 7:59 PM ET
By mutual agreement of Shao-Lee Lin, M.D., Ph.D. and the Company, Dr. Lin stepped down from her position as Chief Executive Officer and as a member of the Board, effective on May 8, 2024.
appointed Senior Vice President and Chief Accounting Officer Jonathan W. (“Butch”) Oorlog, Jr., age 60, as Chief Financial Officer, effective October 1, 2024
On May 20, 2024, the Board of Directors (the “Board”) of Definitive Healthcare Corp. (the “Company”) appointed Kevin Coop to the position of Chief Executive Officer (“CEO”) and as a member of the Board, each effective June 24, 2024 (the “Start Date”).
Effective on the Start Date, Jason Krantz, the Company’s founder, Executive Chairman of the Board and current Interim CEO will step down from his role as Interim CEO and continue to serve as Executive Chairman of the Board.
On May 24, 2024, Collegium Pharmaceutical, Inc. (the “Company”) entered into a letter agreement (the “Letter Agreement”) with Michael Heffernan in connection with Mr. Heffernan’s appointment as Interim President and Chief Executive Officer of the Company.
Also on May 24, 2024, the Company entered into a Separation and Release Agreement with Mr. Ciaffoni (the “Separation Agreement”) in connection with his previously announced departure from the Company.
Appointed
Dr. Rao Mulpuri
Chief Executive Officer
View, Inc.
Filed
May 24, 2024, 7:59 PM ET
Dr. Rao Mulpuri (Chief Executive Officer)
Departed
Christopher Harms
Chief Financial Officer and principal financial and accounting officer
Effective May 24, 2024 (the “Effective Date”), Christopher Harms is no longer serving as Chief Financial Officer and principal financial and accounting officer of Amplitude, Inc. (the “Company”).
Departed
Abigail Jenkins
Chief Executive Officer
Gamida Cell Ltd.
Effective
2024-05-24
Filed
May 24, 2024, 7:59 PM ET
the board of directors of the Company (the “ Board ”) approved on May 16, 2024 the separation of the Company’s Chief Executive Officer, Abigail Jenkins, effective as of the Effective Date.
Recent executive movements from 8-K Item 5.02 filings, source-linked. Cards are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.